D. Branstetter

发表

RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model

J. Canon, R. Bryant, M. Roudier, 2012, Breast Cancer Research and Treatment.

BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.

I. Kola, R. Motter, K. Johnson-wood, 2001, Human molecular genetics.

Application of pharmacodynamic assays in a phase Ia trial of Apo2L/TRAIL in patients with advanced tumors

R. Herbst, D. Branstetter, G. Eckhardt, 2007 .

Reproductive toxicity of denosumab in cynomolgus monkeys.

D. Branstetter, I. Pyrah, R. Boyce, 2013, Reproductive toxicology.

Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours

R. Herbst, D. Branstetter, S. Eckhardt, 2011, British Journal of Cancer.

RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase

Seema A. Khan, D. Branstetter, W. Dougall, 2014, Breast Cancer Research and Treatment.

Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression

W. Woodward, G. Hortobagyi, S. Krishnamurthy, 2017, Breast Cancer Research and Treatment.

A comparison of the lung adenoma response in strain A/J mice after intraperitoneal and oral administration of carcinogens.

D. Branstetter, M. A. Pereira, G. Stoner, 1984, Toxicology and applied pharmacology.

Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection.

D. Branstetter, W. Dougall, Robert E. Miller, 2007, Journal of immunology.

Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

David M. Thomas, J. Blay, D. Branstetter, 2012, Clinical Cancer Research.

RANKL inhibition decreases the incidence of mammary adenocarcinomas in wild type (WT) and MMTV-RANK transgenic mice.

D. Branstetter, W. Dougall, Jon C Jones, 2009 .

Osteoclast Differentiation Is Impaired in the Absence of Inhibitor of κB Kinase α*

S. Akira, J. Derry, K. Takeda, 2004, Journal of Biological Chemistry.

Investigations into biochemical changes due to diurnal variation and estrus cycle in female rats using high-resolution (1)H NMR spectroscopy of urine and pattern recognition.

E Holmes, J C Lindon, D. Branstetter, 2001, Analytical biochemistry.

AMG 655, a fully human agonistic antibody against TRAIL receptor-2, induces apoptosis via caspase activation in vitro and in vivo

A. Coxon, D. Branstetter, I. Foltz, 2007 .

Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells

D. Branstetter, C. Strathdee, Tiep Le, 2007, Apoptosis.

Cancer Therapy : Clinical Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

David M. Thomas, J. Blay, D. Branstetter, 2012 .

Relationship between in utero development of the mouse liver and tumor development following transplacental exposure to ethylnitrosourea.

D. Branstetter, G. Stoner, P. Goldblatt, 1989, Cancer research.

RANK and RANK ligand expression in primary human osteosarcoma

D. Branstetter, W. Dougall, A. Jacob, 2015, Journal of bone oncology.

RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy

C. Sotiriou, S. Loi, M. Piccart, 2015, Breast Cancer Research.

Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma.

A. Belldegrun, B. Seliger, A. Pantuck, 2018, Urologic oncology.

Distribution of RANK and RANK Ligand in Normal Human Tissues as Determined by an Optimized Immunohistochemical Method

E. Manna, D. Branstetter, W. Dougall, 2017, Applied immunohistochemistry & molecular morphology : AIMM.

Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha.

S. Akira, J. Derry, K. Takeda, 2004, The Journal of biological chemistry.

Effect of lung development on the histological pattern of lung tumors induced by ethylnitrosourea in the C3HeB/FeJ mouse.

D. Branstetter, P. P. Moseley, 1991, Experimental lung research.

Effect of gestational development of lung tumor size and morphology in the mouse.

D. Branstetter, G. Stoner, P. Goldblatt, 1988, Cancer research.

Dermatophilosis in two dogs.

D. Branstetter, R. Carithers, M. Abou-Gabal, 1976, Journal of the American Veterinary Medical Association.

Microsporidan infection in the lovebird Agapornis roseicollis

D. Branstetter, S. M. Knipe, 1982 .

In Vitro Mechanistic Toxicology Evaluation of the Antibiotic, Paldimycin Sodium, in Chang Liver Cells

D. Branstetter, D. Linseman, J. Bacon, 1992 .

Ethylnitrosourea-induced transplacental carcinogenesis in the mouse: tumor response, DNA binding, and adduct formation.

D. Branstetter, G. Stoner, P. Goldblatt, 1987, Cancer research.

Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin.

D. Branstetter, D. Linseman, L. A. Hampton, 1995, Fundamental and applied toxicology : official journal of the Society of Toxicology.

An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation.

D. Hume, R. Paxton, D. Branstetter, 2010, Blood.

Reversal of bropirimine developmental toxicity with progesterone.

D. L. Black, D. Branstetter, K. Kirton, 1991, Toxicology and applied pharmacology.

Intravital imaging reveals distinct responses of depleting dynamic tumor-associated macrophage and dendritic cell subpopulations

Z. Werb, D. Branstetter, A. Olow, 2014, Proceedings of the National Academy of Sciences.

RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer

K. Edlund, F. Hirsch, H. Popper, 2017, Genes & development.

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

D. Branstetter, W. Dougall, J. Pinkas, 2010, Nature.

RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers

J. Visvader, G. Smyth, G. Mann, 2016, Nature Medicine.

Progestin effects on cell proliferation pathways in the postmenopausal mammary gland

D. Branstetter, W. Dougall, J. Cline, 2013, Breast Cancer Research.

Metabolism of the HIV-1 reverse transcriptase inhibitor delavirdine in mice.

V. K. Sood, D. Branstetter, M J Hauer, 1997, Drug metabolism and disposition: the biological fate of chemicals.

Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types

A. Coxon, D. Branstetter, I. Foltz, 2010, Cancer biology & therapy.

RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy

C. Sotiriou, S. Loi, M. Piccart, 2015, Breast Cancer Research.

RANK expression as a prognostic and predictive marker in breast cancer

C. Denkert, S. Loibl, M. Werner, 2014, Breast Cancer Research and Treatment.

RANK Overexpression in Transgenic Mice with Mouse Mammary Tumor Virus Promoter-Controlled RANK Increases Proliferation and Impairs Alveolar Differentiation in the Mammary Epithelia and Disrupts Lumen Formation in Cultured Epithelial Acini

H. Dinh, D. Branstetter, W. Dougall, 2006, Molecular and Cellular Biology.

RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.

F. Climent, D. Branstetter, W. Dougall, 2012, Cancer research.

Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity.

T. Bush, Tzu-Hsuan Huang, D. Branstetter, 2014, Cancer cell.

Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors

A. Coxon, D. Branstetter, T. Burgess, 2010, Clinical Cancer Research.

Variability in the developmental toxicity of bropirimine with the day of administration.

D. L. Black, D. Branstetter, K. Kirton, 1990, Teratology.

Induction of a hepatic toxic syndrome in the Dutch-belted rabbit by a quinoxalinone anxiolytic.

R. Ulrich, C. Hunt, D. Branstetter, 1995, Toxicology.

Nectin-like Protein 2 Defines a Subset of T-cell Zone Dendritic Cells and Is a Ligand for Class-I-restricted T-cell-associated Molecule*♦

J. Derry, D. Branstetter, M. Wolfson, 2005, Journal of Biological Chemistry.

Tg.AC Genetically Altered Mouse: Assay Working Group Overview of Available Data

R E Stoll, R L Binder, J F Mahler, 2001, Toxicologic pathology.

P450-mediated O-demethylated metabolite is responsible for rat hepatobiliary toxicity of pyridyltriazine-containing PI3K inhibitors.

D. Branstetter, H. Lebrec, R. Subramanian, 2014, Toxicological sciences : an official journal of the Society of Toxicology.

Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

David M. Thomas, J. Blay, D. Branstetter, 2012, Clinical Cancer Research.

RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.

F. Climent, D. Branstetter, W. Dougall, 2012, Cancer research.

Comparative mutagenicity testing of bropirimine, 3. Bropirimine does not induce cytogenetic damage in vivo in the rat but does produce micronuclei in the mouse.

D. Branstetter, R. Sorg, J. Sams, 1991, Mutation research.

The effect of c-Kit inhibition on mast cells in skin, colon, and lung (39.46)

D. Branstetter, A. Itano, E. Trueblood, 2009, The Journal of Immunology.